The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer.
Alan Adolph Thomay
No relevant relationships to disclose
Stacey Su
No relevant relationships to disclose
Adam J. Friedant
No relevant relationships to disclose
Karen J. Ruth
No relevant relationships to disclose
Igor A. Astsaturov
No relevant relationships to disclose
Barbara Burtness
No relevant relationships to disclose
Crystal Shereen Denlinger
No relevant relationships to disclose
Efrat Dotan
No relevant relationships to disclose
Michael J. Hall
No relevant relationships to disclose
Joshua E. Meyer
No relevant relationships to disclose
Prashant C. Shah
No relevant relationships to disclose
Steven J. Cohen
No relevant relationships to disclose
Walter J. Scott
No relevant relationships to disclose